Modality
ERT
MOA
CAR-T BCMA
Target
Tau
Pathway
Apoptosis
LNCFLGS
Development Pipeline
Preclinical
~Feb 2022
→ ~May 2023
Phase 1
Aug 2023
→ May 2028
Phase 1Current
NCT03751098
1,249 pts·LGS
2023-08→2028-05·Terminated
1,249 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-05-152.1y awayPh2 Data· LGS
Trial Timeline
Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
P1/2
Termina…
Catalysts
Ph2 Data
2028-05-15 · 2.1y away
LGS
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03751098 | Phase 1/2 | LGS | Terminated | 1249 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| TAK-8262 | Takeda | NDA/BLA | Tau | |
| Fixazanubrutinib | Amgen | Phase 2 | PI3Kα | |
| REG-8074 | Regeneron | Phase 2/3 | KRASG12C | |
| JAZ-8729 | Jazz Pharma | Phase 2/3 | FcRn | |
| ACA-2691 | Acadia Pharma | Phase 3 | BCMA | |
| Olpasotorasib | Structure Ther | Preclinical | C5 | |
| AGI-4446 | Agios | Phase 3 | PSMA | |
| TER-5062 | Terns | Phase 2/3 | Tau |